Transgenic enhancement of renal mitochondrial akt1 improved cardiac outcomes in CKM syndrome, suggesting therapeutic potential.
Key Points
Improved cardiac function was observed in mice with enhanced renal mitochondrial akt1, indicating a potential treatment avenue.
Cardiac metrics included raised ejection fraction to 73.6% from 66.4% and reduced left ventricular wall thickness, strengthening the findings.
The intervention led to decreased metabolic dysfunction markers, such as reduced fasting glucose and improved insulin sensitivity, signaling health benefits.
Utilizing transgenic mice, the study highlights potential renal protective strategies for treating cardiovascular-kidney-metabolic syndrome.